INNV-21. FEASIBILITY OF A VIRTUAL REALITY (VR) INTERVENTION TARGETING DISTRESS AND ANXIETY IN PRIMARY BRAIN TUMOR (PBT) PATIENTS AT THE TIME OF NEUROIMAGING: INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL

Amanda King, Kayla Roche, Heather Leeper, Elizabeth Vera, Tito Mendoza, Kelly Mentges, Alvina Acquaye, Kendra Adegbesan, Lisa Boris, Eric Burton, Claudia Chambers, Anna Choi, Alexa Christ, Karen Evans, Ewa Grajkowska, Jason Levine, Matthew Lindsley, Nicole Lollo, Edina Komlodi-Pasztor, Hope MillerMarissa Panzer, Marta Penas-Prado, Valentina Pillai, Lily Polskin, Jennifer Reyes, James Rogers, Solmaz Sahebjam, Dilorom (Delia) Sass, Dorela Shuboni-Mulligan, Macy Stockdill, Brett Theeler, Kathleen Wall, Alex Wollet, Jing Wu, Mark Gilbert, Terri Armstrong

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Purpose: PBT patients experience high levels of distress and anxiety symptoms at the time of neuroimaging (“scanxiety”). This single-arm phase 2 clinical trial interim analysis investigated the feasibility of an immersive VR intervention administered via telehealth for PBT populations. Methods: English-speaking adult patients with upcoming neuroimaging who can self-report symptoms and have reported distress on prior patient-reported outcomes (PROs) were eligible. Exclusion criteria include recent cranial surgery, scalp wounds, or seizures, anxiety disorders, nausea, and visual deficits. The primary intervention is a brief self-selected VR relaxation scenario completed prior to neuroimaging followed by self-directed use for 1 month. PROs are completed before and immediately after the intervention, as well as 1 week and 1 month later, with a qualitative phone interview to assess satisfaction. Results: Fifty-five screened patients were contacted via email with 15 (27%) no responses. 40 patients were approached with 9 (16%) declines, 11 (20%) screen fails, and 20 patients were consented and enrolled. Decline reasons included treatment-related symptoms (11%), no distress or anxiety (30%), and unknown (56%). Screen fail reasons included vertigo and incisional scalp pain (9%), recent seizure activity (9%), diplopia (9%), and anxiety disorders (9% claustrophobia/ panic disorder, 18% PTSD, and 36% GAD). Of those enrolled, 50% were male and the majority were 50 years old (65%), White/ non-Hispanic (90%), and had a KPS score of 90 (85%), a high-grade tumor (65%), and were on active treatment. 100% of enrolled patients completed the VR intervention, weekly check-ins, PRO questionnaires, and qualitative interview. >90% of patients found VR worthwhile, would use VR again, and would recommend VR to other patients for use before clinical evaluations. Conclusions and Implications: These findings suggest that VR intervention is feasible and study continuation is warranted. The high incidence of PTSD and GAD has not been previously reported and necessitates further exploration.
Original languageAmerican English
Pages (from-to)vii145-vii146
JournalNeuro-Oncology
Volume24
Issue numberSupplement_7
DOIs
StatePublished - Nov 2022

Cite this